A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

In a world first, a 15-foot reticulated python named Jodie Foster has successfully undergone electrochemotherapy, a pioneering cancer treatment usually used in humans.

The reticulated python is a species native to South and Southeast Asia. It is the world’s longest snake and the third heaviest.

The 50kg python, named Jodie Foster after the Hollywood star, underwent the treatment after being diagnosed with fibrosarcoma, a malignant tumor, in her jaw. The tumor was initially removed through surgery but later returned and began invading her jawbone.

“Months later, 50kg Jodie Foster is cancer-free and back to her usual ‘bright and feisty’ self,” Chester Zoo in the UK said in a statement.

What Happened To Jodie Foster?

Keepers became concerned when Jodie started eating less and became more inactive. Tests confirmed a fibrosarcoma in her jaw. Vets initially removed the tumor through surgery.

Tests confirmed she had a fibrosarcoma, a malignant tumor, in her jaw. Although vets initially removed the tumor, it later returned and started destroying part of her jawbone. Doctors feared further surgery alone would not be enough and that the tumor could eventually make it difficult for her to eat.

“We were facing the possibility of losing her as the tumor made it more and more difficult for her to eat, so we worked with cancer specialists to see whether we could adapt electrochemotherapy for a snake," said Ian Ashpole, Veterinary Officer at Chester Zoo :

“As far as we're aware, this is the first time it's ever been used in one," Ashpole added.

Also read: Moderna and Merck’s Custom-Made mRNA Cancer Vaccine Shows Promise In Late-Stage Melanoma Trial

How Was The Human Cancer Treatment Adapted For A Snake?

With no operating table large enough for a python of Jodie's size, the veterinary team had to improvise.

For the operation that lasted 90 minutes, Jodie was first anaesthetized in her habitat before being taken to the veterinary center.

Two operating tables were placed together to create a surface roughly the size of a double bed. Heated blankets and warm air were also used to keep her body temperature stable.

Dr. Ashpole first removed the tumor and performed a hemi-mandibulectomy, removing part of the diseased jawbone. Electrochemotherapy was then used to target any remaining cancer cells.

What Is Electrochemotherapy? How Does It Work?

According to Cancer Research UK, electrochemotherapy combines chemotherapy with small electrical pulses.

It is used to treat some cancers that begin in the skin or have spread to the skin. However, its use in Jodie Foster marks a world first in veterinary medicine for a snake.

“Electrochemotherapy is an emerging treatment, and this was the first time it had been used in a snake,” said Jose Alvares Picornell, Department of Small Animal Clinical Science, University of Liverpool, who was part of the three-hour-long surgery.

The treatment combines the cancer drug bleomycin with carefully controlled electrical pulses delivered directly to the tumor site.

• The electrical pulses temporarily make cancer cells more permeable.
• This allows the drug to enter the cells more effectively.
• The approach can allow lower doses of chemotherapy to be used.
• It can sometimes be delivered in a single procedure.

Read More: Microplastics Found In Anchovies’ Edible Muscle: What It Means For Brain Health

Jodie Foster Back 'Bright And Feisty'

Despite losing part of her jawbone, Jodie's appetite and hunting ability have not been affected, the Zoo officials said, adding that she continues to strike, grip and swallow food without difficulty.

Months of observation have shown no problems with feeding, and a final check confirmed that she remains free of signs of the cancer returning. The officials added that Jodie is eating normally, exploring her habitat and behaving as usual.

“Seeing her back to her normal bright and feisty self has been incredibly rewarding. A few months ago, we genuinely didn't know whether she'd survive," Dr Ashpole added.

Delhi is witnessing a significant rise in influenza A H1N1 infections, with the cumulative tally reportedly reaching 1,777.

As per National Centre for Disease Control (NCDC) data, Delhi recorded 1,449 H1N1 cases up to August 12, more than six times the 229 cases reported during the same period last year. Mumbai and Bengaluru are also reporting a sharp rise in cases.

Health Ministry Reviews H1N1 Preparedness

Amid the rise, Union Health Minister JP Nadda reviewed preparedness, including:

• Hospital bed availability
• Critical care facilities
• Essential medical supplies
• Influenza surveillance and epidemiological trends
• ILI and SARI trends
• Testing and laboratory surveillance
• Healthcare facilities’ preparedness

The “situation is being closely and continuously monitored”, said Nadda. The Health Minister also emphasized continued vigilance, robust surveillance and proactive preparedness, along with respiratory and hand hygiene.

People with persistent or severe respiratory symptoms, breathing difficulty or other warning signs were advised to seek medical attention promptly.

The Health Ministry is coordinating with States/UTs, hospitals, laboratories and other stakeholders for early detection, timely clinical management and effective surveillance of seasonal influenza, including H1N1.

Doctors Flag Atypical H1N1 Symptoms

Dr. Atul Kakkar, Senior Consultant and Head of Department, Internal Medicine, Sir Gangaram Hospital, told HealthandMe that H1N1 cases are significantly higher than last year, possibly partly due to seasonal changes.

Most patients are presenting with flu-like symptoms, cold, cough, body aches, and upper respiratory tract infections.

However, doctors are also seeing atypical symptoms.

“We are seeing patients having diarrhea also and myalgias, which are getting very, very frequent.”

Patients at extreme ages are more prone to complications and may require oxygen, high-flow oxygen, NIV or BiPAP, he said.

Those at higher risk include people who are unvaccinated against flu, patients undergoing chemotherapy, and those with COPD, bronchial asthma, cancer or on immunosuppressive treatment.

“Evidence shows early antiviral treatment reduces complications and hospital stay, so we must expand rapid diagnostic capacity across primary care centres and ensure affordable antivirals are available at the point of care,” Dr. Sabine Kapasi, Global Health Strategist and UN Advisor, told HealthandMe.

What Is H1N1?

H1N1 is a subtype of influenza A virus. Common symptoms include:

• Fever
• Cough
• Sore throat
• Runny or blocked nose
• Headache
• Fatigue
• Body aches
• Vomiting or diarrhoea, particularly in some children

The virus mainly spreads through respiratory droplets when an infected person coughs, sneezes or talks.

Children can also spread the virus before they realize they are sick.

Red-flag symptoms include:

• Persistent high fever
• Worsening breathlessness
• Chest pain
• Confusion
• Inability to drink

H1N1 Can Affect The Heart

As per experts, H1N1 infection may also be associated with cardiovascular complications, including:

• Heart inflammation
• Abnormal heartbeats
• Worsening heart failure

Dr. Saurabh Gupta, Associate Director, Internal Medicine, Yashoda Medicity, said H1N1 may cause fluctuations in heart rhythm or inflammation involving the heart.

“Those with pre-existing heart conditions should be more vigilant whilst they’re recuperating. As the infection puts more work on the body, you can find that previous heart problems are more noticeable,” he added.

Warning Signs After H1N1

People recovering from H1N1 should seek medical attention if they develop:

• Severe chest pain
• Shortness of breath
• High or fluttering pulse
• Sudden faintness
• Severe weakness.

Research shows that there are an estimated 300 to 450 living supercentenarians—people aged 110 or older—around the world at any given time. Japan is particularly known for healthy ageing, with an average life expectancy of over 84 years and nearly 100,000 centenarians.

While maintaining a healthy and balanced lifestyle may partly explain their longevity, a new study by a A team of Japanese scientists suggests that it may also be linked to an abundance of cancer-fighting immune cells.

The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers.

When a person gets sick, these cells multiply through a process called clonal expansion to help fight infection.

The study, published in the journal Cell Reports, showed that these immune cells may also play a role in healthy ageing among supercentenarians.

“Immune aging is not simply a process of decline,” said first author Kosuke Hashimoto, an associate professor at the University of Osaka in Japan.

“The selective expansion of certain T cells suggests that, even in extreme old age, the immune system may continue to adapt to age-related challenges,” Hashimoto added.

How Do Immune Cells Work In Supercentenarians?

CD4 CTLs are a cellular signature of supercentenarians—people who live to age 110 and beyond. The researchers discovered that these cells expand and adapt within this older population.

“CD4 CTLs are an atypical and relatively rare T cell population,” Hashimoto said. “So, their marked increase in supercentenarians may provide important clues as to how the immune system is maintained in extreme old age.”

What Did the Study Find?

The small study analyzed blood samples from 28 adults divided into three age groups:

• 70–99
• 100–109
• 110 and older

The findings showed that the proportion of CD4 CTLs increased with age, with median percentages of 4%, 9.6% and 17.6%, respectively.

Researchers found that older adults may be responding to persistent immune threats. As a result, CD4 CTLs clone themselves when the immune system is under attack.

The most prominent clone accounted for an average of 33.3% of CD4 CTLs, indicating that older adults may be responding to persistent immune threats. In one centenarian’s blood sample, a single clone accounted for 53.8% of their CD4 CTLs.

Next, researchers matched the receptor sequences of each participant’s top CD4 CTL clone with those in a public database. Nearly three dozen matches belonged to people with cancer, namely lung, breast and liver cancers.

Because none of the centenarians or supercentenarians studied had been diagnosed with these cancers, researchers theorized that their CD4 CTL expansion may reflect early immune responses.

“Some CD4 CTLs may recognize cancer-related targets, although their exact targets remain unknown,” Hashimoto said.

Evidence Remains Preliminary

The study, which focused on T cells circulating in the blood, does not prove that having an abundance of CD4 CTLs prevents cancer or causes a person to live longer.

Hashimoto said the team’s next step is to research how these cells behave in human tissues.

“As we age, abnormal cells, including senescent and cancerous cells, become more common,” Hashimoto said. “Our findings suggest that immune adaptation to these changes may contribute to exceptional longevity.”